Program Information
Quantitative CBCT Parameters for Evaluation EGFR Mutation Status and Prediction EGFR-TKI Response in Patients with Lung Adenocarcinoma
Q Wen*, J Zhu , X Meng , Y Yin , J Yu , Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong
Presentations
WE-RAM1-GePD-J(B)-1 (Wednesday, August 2, 2017) 9:30 AM - 10:00 AM Room: Joint Imaging-Therapy ePoster Lounge - B
Purpose: The aim of this study is correlating changes of cone beam computed tomography (CBCT) variables during radiotherapy course in patients with lung carcinoma, investigating their relationships with epidermal growth factor receptor (EGFR) mutation status and TKI (tyrosine kinase inhibitor) response.
Methods: A total of 126 patients with inoperable and locally advanced lung adenocarcinoma who received radiotherapy and had CBCT were involved in this study. The changes of quantitative variables were extracted from the first and last time of radiotherapy course of each primary tumor.EGFR mutation status was determined by immunohistochemistry. The relationships between CBCT variables were compared between different EGFR mutation status and TKI response.
Results: EGFR mutation was detected in 56/126 (44.4%) and 24 patients (42.8 %) were response to EGFR-TKI based on the RECIST criteria. We observed that mutant EGFR was statistically significant associated with the changes of tumor volume (P = 0.042) and skewness (P = 0.013) in multivariate analysis. In the group of TKI, the change of size-zone (P < 0.001), intensity variability (P= 0.014) and kurtosis (P = 0.036) were detected significantly decrease in TKI responder group. And size-zone (P < 0.001) and intensity variability (P = 0.037) were regarding as independent predictors for response to TKI.
Conclusion: The change of quantitative CBCT variables have potential to provide information regarding tumor phenotype and significant change of quantitative variable could be predictors of TKI response in patients with mutant EGFR.
Funding Support, Disclosures, and Conflict of Interest: National Natural Science Foundation of China (Grant No.81671785),Special foundation for Scientific Research in Public Interest of China (Grant No.201402011) and Shandong Provincial Key Project of Translational Medicine (Grant No.ZR2015HZ004).
Contact Email: